Tags

Type your tag names separated by a space and hit enter

Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
Vaccine. 2012 Nov 06; 30(48):6897-902.V

Abstract

BACKGROUND

Pertussis toxin (PT) is a specific virulence factor of Bordetella pertussis and it is included in all acellular pertussis vaccines (aP). Although immunity after infection seems to persist longer than that after vaccination, the exact mechanism(s) is not known. Primary aim of this study was to develop an ELISA method for measuring avidity index (AI) of IgG-anti-PT antibodies and to compare antibody responses after booster vaccination and infection. Secondary aim was to evaluate if the AI-ELISA has potential in the serodiagnosis of pertussis.

MATERIAL

Serum samples from a total of 409 subjects were included in the study. Paired sera were taken from 97 adolescents who received booster vaccine ten years ago (dTpa-004) and from 80 young adults who received a second booster dose ten years after the previous booster vaccine (dTpa-040). Thirty-two paired sera from culture-confirmed pertussis patients, 161 single sera from serologically diagnosed patients and 39 single sera from healthy controls were included. AI of IgG-anti-PT antibodies were determined with newly developed ELISA using diethylamine (DEA) as a bond breaking agent. The IgG-anti-PT antibodies were measured by standardized ELISA.

RESULTS

A significant increase was found in antibody concentrations and AI between PRE and one month POST vaccination ten years ago [GMC for antibody: 7.9 IU/ml vs. 98.3 IU/ml (p=0.0001); for AI: 40.4% vs. 56.1% (p=0.0001)]. Similar result was observed after the second booster dose [GMC for antibody: 9.2 IU/ml vs. 92.4 IU/ml (p=0.0001); for AI: 36.1% vs. 59.5% (p=0.0001)] and between the first and second sera of culture-confirmed patients [GMC for antibody: 6.9 IU/ml vs. 285.1 IU/ml (p=0.0001); for AI: 40.5% vs. 68.4% (p=0.0001)]. Healthy controls showed lower levels of both antibodies and AI.

CONCLUSIONS

Our results suggest that there may be difference in quality and quantity of antibodies to PT after vaccination and after infection. Furthermore, AI could be a help for vaccine studies.

Authors+Show Affiliations

Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Turku, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22981763

Citation

Barkoff, Alex-Mikael, et al. "Differences in Avidity of IgG Antibodies to Pertussis Toxin After Acellular Pertussis Booster Vaccination and Natural Infection." Vaccine, vol. 30, no. 48, 2012, pp. 6897-902.
Barkoff AM, Gröndahl-Yli-Hannuksela K, Vuononvirta J, et al. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine. 2012;30(48):6897-902.
Barkoff, A. M., Gröndahl-Yli-Hannuksela, K., Vuononvirta, J., Mertsola, J., Kallonen, T., & He, Q. (2012). Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine, 30(48), 6897-902. https://doi.org/10.1016/j.vaccine.2012.09.003
Barkoff AM, et al. Differences in Avidity of IgG Antibodies to Pertussis Toxin After Acellular Pertussis Booster Vaccination and Natural Infection. Vaccine. 2012 Nov 6;30(48):6897-902. PubMed PMID: 22981763.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. AU - Barkoff,Alex-Mikael, AU - Gröndahl-Yli-Hannuksela,Kirsi, AU - Vuononvirta,Juho, AU - Mertsola,Jussi, AU - Kallonen,Teemu, AU - He,Qiushui, Y1 - 2012/09/13/ PY - 2012/06/05/received PY - 2012/08/14/revised PY - 2012/09/02/accepted PY - 2012/9/18/entrez PY - 2012/9/18/pubmed PY - 2013/4/13/medline SP - 6897 EP - 902 JF - Vaccine JO - Vaccine VL - 30 IS - 48 N2 - BACKGROUND: Pertussis toxin (PT) is a specific virulence factor of Bordetella pertussis and it is included in all acellular pertussis vaccines (aP). Although immunity after infection seems to persist longer than that after vaccination, the exact mechanism(s) is not known. Primary aim of this study was to develop an ELISA method for measuring avidity index (AI) of IgG-anti-PT antibodies and to compare antibody responses after booster vaccination and infection. Secondary aim was to evaluate if the AI-ELISA has potential in the serodiagnosis of pertussis. MATERIAL: Serum samples from a total of 409 subjects were included in the study. Paired sera were taken from 97 adolescents who received booster vaccine ten years ago (dTpa-004) and from 80 young adults who received a second booster dose ten years after the previous booster vaccine (dTpa-040). Thirty-two paired sera from culture-confirmed pertussis patients, 161 single sera from serologically diagnosed patients and 39 single sera from healthy controls were included. AI of IgG-anti-PT antibodies were determined with newly developed ELISA using diethylamine (DEA) as a bond breaking agent. The IgG-anti-PT antibodies were measured by standardized ELISA. RESULTS: A significant increase was found in antibody concentrations and AI between PRE and one month POST vaccination ten years ago [GMC for antibody: 7.9 IU/ml vs. 98.3 IU/ml (p=0.0001); for AI: 40.4% vs. 56.1% (p=0.0001)]. Similar result was observed after the second booster dose [GMC for antibody: 9.2 IU/ml vs. 92.4 IU/ml (p=0.0001); for AI: 36.1% vs. 59.5% (p=0.0001)] and between the first and second sera of culture-confirmed patients [GMC for antibody: 6.9 IU/ml vs. 285.1 IU/ml (p=0.0001); for AI: 40.5% vs. 68.4% (p=0.0001)]. Healthy controls showed lower levels of both antibodies and AI. CONCLUSIONS: Our results suggest that there may be difference in quality and quantity of antibodies to PT after vaccination and after infection. Furthermore, AI could be a help for vaccine studies. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22981763/Differences_in_avidity_of_IgG_antibodies_to_pertussis_toxin_after_acellular_pertussis_booster_vaccination_and_natural_infection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(12)01302-3 DB - PRIME DP - Unbound Medicine ER -